Thiazolidinediones (TZDs) target peroxisome proliferator-activated receptor-gamma (PPAR-gamma) and are widely prescribed to treat type 2 diabetes but are associated with substantial weight gain. This side effect of TZDs is now shown to be mediated via brain PPAR-gamma. These findings suggest an important role for brain PPAR-gamma in obesity and have major implications for the clinical use of TZDs (pages 623-626 and 618-622).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据